Summary
Chairpersons: Prof. Francesco Cosentino (ESC), Dr. Subodh Verma (Toronto, CA), Dr Philip Ambery (AstraZeneca), Dr Martin van Eickels (Bayer), Dr Marianne Bach-Treppendahl (Novo Nordisk)
Replay session 1
Replay session 2
Replay session 3
Replay session 4
Replay session 5
Replay: Closing Lecture
Objectives of the meeting
A significant number of patients with cardiovascular disease (CVD) have concomitant metabolic comorbidities which play a causal and/or permissive role in adverse prognosis.
- The primary objective of the meeting is to improve the recognition and treatment of CVD in patients with multiple metabolic comorbidities.
- The meeting also aims to assess potential mechanism-based approaches to intervention across multiple disorders.
Questions to be addressed
- How can we improve recognition and treatment of cardiovascular disease in patients with obesity, insulin resistance, NASH, and renal disease when associated with metabolic comorbidity?
- How can we improve the recognition and treatment of metabolic and renal disease in patients at the cardiology clinic?
- Are there mechanism-based approaches that can address multiple pathologies across diseases?
- What is important to patients with cardiovascular and metabolic diseases? How can we meet their needs?
- Why may COVID-19 be particularly damaging for patients with cardiovascular and metabolic disease?
- Can we move from broad regulatory definitions to better targeting patients with multiple comorbidities?
Programme
12 May |
09:00 – 16:00 Local time (Western European Time) |
|
09:00 – 09:10 |
Welcome – Introduction and objectives of the meeting Chairpersons |
|
09:10 – 09:40 |
Session I - Common soil and common targets for CKD, NASH and HF? |
|
10 min presentations |
The epidemiological basis Prof. Philip Newsome (Birmingham) - via Zoom What are the biological underpinnings of the relationship between metabolic and cardiovascular disease? Prof. Faiez Zannad (Nancy) What are the clinical and practical implications for physicians as it relates to this interface? Prof. Per-Henrik Groop (Helsinki) |
|
09:40 – 10:00 |
Discussion |
|
10:00 - 10:30 |
Session II – Unravelling the relationships between obesity and CKD in patients with CV disease |
|
10 min presentations |
Epidemiology and natural history of this relationship Prof. Paola Fioretto (Padova) Obesity and HFpEF – common soil? Prof. Lars Lund (Stockholm) - via Zoom Obesity paradox Prof. Stefan Anker (Berlin) |
|
10:30 - 10:45 |
Discussion |
|
10:45 - 11:05 |
Break |
|
11:05 - 11:35 |
Session III - COVID-19: a new threat at the cross-roads between cardiovascular and metabolic diseases |
|
10 min presentations |
How metabolic derangements affect the incidence and natural history of COVID-19 Prof. Naveed Sattar (Glasgow) - via Zoom CV derangement in COVID-19 Prof. Scott S. Solomon (Boston) What are the practical management implications of cardiometabolic disease in patients with COVID-19 Prof. Kamlesh Khunti (Leicester) |
|
11:35 - 12:00 |
Discussion |
|
12:00 - 12:15 |
Session IV - A patient’s perspective on heart failure, renal disease and diabetes.
|
|
12:15 - 12:45 |
Discussion |
|
12:45 - 13:45 |
Lunch |
|
13:45 - 14:15 |
Session V - Mechanisms of chronic cardiometabolic diseases and opportunities for intervention. |
|
10 min presentations |
Sex differences in cardiometabolic risk and opportunities for intervention Circulating biomarkers and their utility in cardiometabolic disease Prof. Andreas M. Zeiher (Frankfurt) Reversal of Pro-vascular Regenerative Cell Exhaustion in Diabetes and Obesity Dr. David Hess (Toronto) |
|
14:15 - 14:35 |
Discussion |
|
14:35 - 14:55 |
Lecture – Health and economics consequences of obesity |
|
Questions to be addressed |
|
|
14:55 - 16:00 |
Panel discussion |
|
16:00 |
Wrap-up – Next steps – A publication |
Our mission: To reduce the burden of cardiovascular disease.